| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Pentoxifylline (also known as oxpentifylline, theobromine, dimethyloxohexylxanthine, EHT 0202, BL 191, BL-191; PTX, pentoxifilina, Trental), a xanthine derivative, is a nonselective PDE inhibitor used as a drug to treat muscle pain in people with peripheral artery disease. It is generic and sold under many brand names worldwide. Its primary use in medicine is to reduce pain, cramping, numbness, or weakness in the arms or legs which occurs due to intermittent claudication, a form of muscle pain resulting from peripheral artery diseases. This is its only FDA, MHRA and TGA-labelled indication. However, pentoxifylline is also recommended for use off license as an adjunct to compression bandaging for the treatment of chronic venous leg ulcers by SIGN as this has been shown to improve healing rates
| ln Vitro |
Pentoxifylline suppresses cell growth in a dose-dependent manner (0.1–50 mM; 24-48 hours) [3]. In MDA-MB-231 cells, pentoxifylline (0.5 mM; 12-36 hours) decreases autophagy and promotes apoptosis [3]. In MDA-MB-231 cells, pentoxifylline (0.5 mM; 12-36 hours) promotes autophagy [3]. The G0/G1 phase of the cell cycle is blocked by pentoxifylline (0.5 mM; 24-48 hours) [3]. Elevated LC3-II/LC3 ratio is brought on by pentoxifylline [3].
|
|---|---|
| ln Vivo |
In rats exposed to transitory global ischemia, pentoxifylline (200 mg/kg; i.p.) exerts a protective effect and lessens cognitive damage [4].
|
| Cell Assay |
Cell proliferation assay[3]
Cell Types: MDA-MB-231 Cell Tested Concentrations: 0.1 mM, 1 mM, 5 mM, 10 mM, 50 mM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Inhibition of cell proliferation in a dose-dependent manner. Apoptosis analysis[3] Cell Types: MDA-MB-231 Cell Tested Concentrations: 0.5 mM Incubation Duration: 12 hrs (hours), 24 hrs (hours), 36 hrs (hours) Experimental Results: Induction of apoptosis. Autophagy assay [3] Cell Types: MDA-MB-231 Cell Tested Concentrations: 0.5 mM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Approximately 20-28% of autophagy was induced. Cell cycle analysis [3] Cell Types: MDA-MB-231 Cell Tested Concentrations: 0.5 mM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Induced G0/G1 phase arrest. Western Blot Analysis[3] Cell Types: MDA-MB-231 Cell Tested Concentrations: 0.5 mM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Induction of high LC3-II/LC3 ratio. |
| Animal Protocol |
Animal/Disease Models: Adult male Wistar rats, 12-13 weeks old (250-300 g) [4]
Doses: 200 mg/kg Route of Administration: intraperitoneal (ip) injection, 1 hour before ischemia and 3 hrs (hrs (hours)) after ischemia. Experimental Results: Significant Improves spatial memory and memory abilities. The effect was Dramatically different from that of the sham operation group and the vehicle group. |
| References |
[1]. Iffat Hassan, et al. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014 Oct-Dec; 5(4): 510–516.
[2]. A Ward, et al. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34(1):50-97. [3]. Yessica Cristina Castellanos-Esparza, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52(4):1246-1254. [4]. Shabnam Movassaghi, et al. Effect of Pentoxifylline on Ischemia- induced Brain Damage and Spatial Memory Impairment in Rat. Iran J Basic Med Sci. 2012 Sep-Oct; 15(5): 1083-1090. |
| Molecular Formula |
C13H18N4O3
|
|---|---|
| Molecular Weight |
278.30702
|
| CAS # |
6493-05-6
|
| Related CAS # |
Pentoxifylline-d6;1185878-98-1;Pentoxifylline-d5;1185995-18-9
|
| SMILES |
c12c(n(c(=O)n(c1=O)CCCCC(C)=O)C)ncn2C
|
| InChi Key |
BYPFEZZEUUWMEJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
|
| Chemical Name |
1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion
|
| Synonyms |
Dimethyloxohexylxanthine; EHT-0202, EHT0202, EHT 0202; BL 191, BL191, BL-191; Oxpentifylline, Pentoxifilina, Theobromine, Trental, Vazofirin, Etazolate
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~93.3 mg/mL (~335.24 mM)
DMSO : ≥ 2.8 mg/mL (~10.06 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 110 mg/mL (395.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5931 mL | 17.9656 mL | 35.9312 mL | |
| 5 mM | 0.7186 mL | 3.5931 mL | 7.1862 mL | |
| 10 mM | 0.3593 mL | 1.7966 mL | 3.5931 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA